Myricetin: A Significant Emphasis on Its Anticancer Potential via the Modulation of Inflammation and Signal Transduction Pathways

Abstract

Cancer is a major public health concern worldwide and main burden of the healthcare system. Regrettably, most of the currently used cancer treatment approaches such as targeted therapy, chemotherapy, radiotherapy and surgery usually cause adverse complications including hair loss, bone density loss, vomiting, anemia and other complications. However, to overcome these limitations, there is an urgent need to search for the alternative anticancer drugs with better efficacy as well as less adverse complications. Based on the scientific evidences, it is proven that naturally occurring antioxidants present in medicinal plants or their bioactive compounds might constitute a good therapeutic approach in diseases management including cancer. In this regard, myricetin, a polyhydroxy flavonol found in a several types of plants and its role in diseases management as anti-oxidant, anti-inflammatory and hepato-protective has been documented. Moreover, its role in cancer prevention has been noticed through modulation of angiogenesis, inflammation, cell cycle arrest and induction of apoptosis. Furthermore, myricetin plays a significant role in cancer prevention through the inhibition of inflammatory markers such as inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (Cox-2). Moreover, myricetin increases the chemotherapeutic potential of other anticancer drugs through modulation of cell signaling molecules activity. This review elaborates the information of myricetin role in cancer management through modulating of various cell-signaling molecules based on in vivo and in vitro studies. In addition, synergistic effect with currently used anticancer drugs and approaches to improve bioavailability are described. The evidences collected in this review will help different researchers to comprehend the information about its safety aspects, effective dose for different cancers and implication in clinical trials. Moreover, different challenges need to be focused on engineering different nanoformulations of myricetin to overcome the poor bioavailability, loading capacity, targeted delivery and premature release of this compound. Furthermore, some more derivatives of myricetin need to be synthesized to check their anticancer potential.

Identification of hub genes and potential molecular mechanisms related to drug sensitivity in acute myeloid leukemia based on machine learning

“…It has been shown to target the Hedgehog signaling pathway ( Tibes et al, 2015 ). Myricetin is a polyhydroxy flavonol found in a several types of plants and plays a significant role in cancer prevention via inhibiting the inflammatory markers, such as inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (Cox-2) ( Rahmani et al, 2023 ). Moreover, myricetin increases the chemotherapeutic potential of other anticancer drugs through modulation of cell signaling activities ( Rahmani et al, 2023 ).…”

Transcriptome and metabolome analysis reveals the effect of flavonoids on flower color variation in Dendrobium nobile Lindl.

“…This may play the same role or provide new guidance in obtaining more Gardenia yellow pigment from G. jasminoides var. radicans Makikno ( Wu et al., 2020 ), extracting flavonoids from flowers ( Mlcek et al., 2021 ), and using myricetin and kaempferol as anticancer substances ( Rahmani et al., 2023 ).…”

Pharmacological Potential of Kaempferol, a Flavonoid in the Management of Pathogenesis via Modulation of Inflammation and Other Biological Activities

“…Interestingly, many therapeutic drugs used today have their roots in natural resources like alkaloids, taxanes, and flavonoids [92]. There has been a growing interest in using natural compounds in chemotherapy to enhance the effectiveness of anti-neoplastic drugs [93] and inhibit cancer growth through the modulation of cell signaling molecules [94][95][96][97][98]. Kaempferol has confirmed the anti-cancer role by modulating different cell signaling molecules (Table 5 and Figure 4).…”